Welcome to the ERACODA website
The European Renal Association COVID-19 Database is a European database collecting clinical information of patients on kidney replacement therapy with COVID-19.
Please note that since May 1st the international database has been closed for first presentations of COVID-19. Since we also collect data at the time point 3 months after the COVID-19 diagnosis, this implicates that the final date on which data will be collected is July 31st, 2021. After this date, you can still enter data in REDCap if you wish (for your own records), but we will no longer perform validations on data entered in the database.
On May 1st the database included about 4500 records (74% dialysis patients and 26% kidney transplant recipients). Furthermore, follow-up data 3 months after COVID-19 diagnosis has been completed for 2210 patients and 110 centers have returned the ERACODA center questionnaire (80% of all active centers).
More than 225 clinicians representing approximately 141 centres from 33 countries (mostly in Europe and brodering the Mediterranean Sea) have contributed data to ERACODA.
The mission of ERACODA is to gain insight in what the COVID-19 epidemic means for patients treated with dialysis or a kidney transplantation across Europe, in the hope to improve their prognosis by intervening on modifiable risk factors.
The primary aim of ERACODA is to investigate the clinical course and outcomes (including hospital admission, intensive care admission and mortality) of patients on kidney replacement therapy with COVID-19. Such information may guide clinical treatment decisions and support triage strategies for admission to critical care units.
A secondary aim is to gain information on risk factors for mortality. Knowledge on modifiable patient and treatment characteristics associated with outcome may lead to interventions or changes in transplantation strategies that can improve prognosis.
What data are collected?
Data are collected from all outpatient and hospitalized adult patients (aged ≥18 years) with a functioning kidney allograft or on maintenance dialysis treatment who are diagnosed with COVID-19. This diagnosis needs to be based on a positive result on a real-time polymerase chain reaction (PCR) assay of nasal or pharyngeal swab specimens, and/or compatible findings on a CT scan or chest X-ray of the lungs.
Patient characteristics
including age, sex, primary kidney disease, comorbi-dities, medication, frailty, mental & functional status
Disease characteristics
including COVID-19 symptoms, vital signs, laboratory test results, hospital & ICU admissions
Center characteristics
including country / region, size, staff, type of screening and preventive strategies applied